Please login to the form below

Not currently logged in
Email:
Password:

Parkinson's disease

This page shows the latest Parkinson's disease news and features for those working in and with pharma, biotech and healthcare.

Lundbeck signs $1.1bn deal for Prexton and Parkinsons drug

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Lundbeck bolstered its R&D pipeline ahead of the weekend with a 900m ($1.1bn) deal to acquire Prexton Therapeutics and its mid-stage Parkinson’s disease (PD) candidate foliglurax. ... movements, and difficulty starting movements known as 'freezing'

Latest news

  • Biogen pays $590m for Pfizer cognition drug Biogen pays $590m for Pfizer cognition drug

    The biotech company has also been linked to a possible takeover offer for Acorda Therapeutics and its Parkinson’s diseases candidates Inbrija (inhaled levodopa) and SYN-201. ... of Parkinson’s disease-related dementia.

  • After Axovant shock, Roivant pens diabetes deal with Poxel After Axovant shock, Roivant pens diabetes deal with Poxel

    After Axovant shock, Roivant pens diabetes deal with Poxel. Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal. ... and sleep disorders in Lewy body dementia and dementia associated with Parkinson’s disease.

  • Smart watch epilepsy monitor cleared by FDA Smart watch epilepsy monitor cleared by FDA

    The market for wearable devices with healthcare applications is estimated to be around $6bn at the moment, ranging from activity monitors through to diagnostic and disease management aids. ... Last year, trials started of a smart watch intended to

  • Smartphone monitoring shows its worth in Roche MS trial Smartphone monitoring shows its worth in Roche MS trial

    The data “support FLOODLIGHT as a potential complement to in-clinic testing to provide a more complete and consistent picture of a patient’s disease progression”, said Roche, adding that the ... The company has also put an app for Parkinson’s

  • Axovant joins ever-growing Alzheimer’s failure club Axovant joins ever-growing Alzheimer’s failure club

    unrelenting series of failures in Alzheimer’s disease trials over the past decade and a half. ... DLB as well as for Parkinson’s disease dementia (PDD), with two other dementia candidates (RVT-103 and RVT-104) in early-stage development.

More from news
Approximately 27 fully matching, plus 188 partially matching documents found.

Latest Intelligence

  • A quest for innovative solutions A quest for innovative solutions

    It is this quest for technology that can help patients with epilepsy and Parkinson’s, the sweet spots in its global operation that saw total revenue grow to 4.2bn in ... We have huge support to translate that change for both others in the organisation

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinsons house'

    But this elegant home, surrounded by manicured lawns, is wired to beat the scourge of Parkinson’s disease. ... first patient for a Parkinson’s disease clinical trial.

  • Pharma deals continue to slide Pharma deals continue to slide

    an antibody for treatment of Parkinson’s disease. ... MEDI1341, an alpha-synuclein antibody entering phase I for treatment of Parkinson’s disease.

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    Normally there is a fear that a condition or disease might not be seen as credible. ... And on the Wednesday I got news that I had prostate cancer and Parkinson’s disease… But when we went into the living room I went, phrrhrht, ”he said, blowing a

  • Digital disruption Digital disruption

    Starting with projects in schizophrenia and Parkinson’s disease, Lundbeck and IBM will also work together to identify potential new drug targets and alternative indications. ... and chronic disease management, starting with respiratory and central

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    He said: “I am thrilled to join Voyager at this important time during the company’s evolution. ... Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis. ... future. “ At the same time we welcome Dennis as a new member of

  • Voyager Therapeutics appoints chief financial officer Voyager Therapeutics appoints chief financial officer

    This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a ... I am thrilled to join the Voyager team and meaningfully contribute

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

  • Acorda Therapeutics appoints chief medical officer Acorda Therapeutics appoints chief medical officer

    This will benefit Acorda's entire pipeline, including our late-stage development programs, CVT-301 and tozadenant for Parkinson's disease.”.

More from appointments
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics